Sunitinib (sutent) - Cancer Science

Relevant Publications

Ripretinib versus sunitinib in patients with advanced gastrointestinal stromal tumor after treatment with imatinib: a plain language summary of the phase 3 INTRIGUE trial.

Issue Release: 2023

Targeting DRD2 by the antipsychotic drug, penfluridol, retards growth of renal cell carcinoma via inducing stemness inhibition and autophagy-mediated apoptosis.

Issue Release: 2022

Neuropilin 1 and Neuropilin 2 gene invalidation or pharmacological inhibition reveals their relevance for the treatment of metastatic renal cell carcinoma.

Issue Release: 2021

Hand-Foot Skin Reaction Secondary to Sunitinib in a Patient With Metastatic Clear Cell Renal Cell Carcinoma.

Issue Release: 2021

Nitrogen-Containing Heterocycles as Anticancer Agents: An Overview.

Issue Release: 2020

Osteonecrosis of the jaws produced by sunitinib: a systematic review.

Issue Release: 2019

Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation.

Issue Release: 2018

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.

Issue Release: 2018

Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.

Issue Release: 2018

Medication related osteonecrosis of the jaws associated with targeted therapy as monotherapy and in combination with antiresorptives. A report of 7 cases from the Copenhagen Cohort.

Issue Release: 2017

Tyrosine kinase inhibitor sunitinib therapy is effective in the treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.

Issue Release: 2016

5-Hydroxy-7-azaindolin-2-one, a novel hybrid of pyridinol and sunitinib: design, synthesis and cytotoxicity against cancer cells.

Issue Release: 2016

L1-CAM knock-down radiosensitizes neuroblastoma IMR-32 cells by simultaneously decreasing MycN, but increasing PTEN protein expression.

Issue Release: 2016

Response to sunitinib (Sutent) in chemotherapy refractory clear cell ovarian cancer.

Issue Release: 2016

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry.

Issue Release: 2016

Synthesis and preliminary evaluation of 5,7-dimethyl-2-aryl-3H-pyrrolizin-3-ones as angiogenesis inhibitors.

Issue Release: 2016

Drug-induced mitochondrial dysfunction and cardiotoxicity.

Issue Release: 2015

Hypercalcemia of Malignancy.

Issue Release: 2015

Combining radiotherapy with sunitinib: lessons (to be) learned.

Issue Release: 2015

Current management of patients with gastrointestinal stromal tumor receiving the multitargeted tyrosine kinase inhibitor sunitinib.

Issue Release: 2015

What Happens After the Trial?

What Are Cancer Awareness Events?

Are There Specific Foods That Can Help Manage Side Effects?

How Can Cancer Patients Access PAF Services?

What is Herbal Medicine?

What Steps Can Be Taken for a Smooth Transition from Hospital to Home?

What is Mucinous Adenocarcinoma of the Colon?

Is Supplementation Necessary?

What is the Metabolic Hypothesis of Cancer?

How are Opioid Analgesics Administered?

Partnered Content Networks

Relevant Topics